↓ Skip to main content

Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study

Overview of attention for article published in "The Lancet Psychiatry", July 2016
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#3 of 1,351)
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (98th percentile)

Citations

dimensions_citation
184 Dimensions

Readers on

mendeley
642 Mendeley
Title
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study
Published in
"The Lancet Psychiatry", July 2016
DOI 10.1016/s2215-0366(16)30065-7
Pubmed ID
Authors

Robin L Carhart-Harris, Mark Bolstridge, James Rucker, Camilla M J Day, David Erritzoe, Mendel Kaelen, Michael Bloomfield, James A Rickard, Ben Forbes, Amanda Feilding, David Taylor, Steve Pilling, Valerie H Curran, David J Nutt

Abstract

Psilocybin is a serotonin receptor agonist that occurs naturally in some mushroom species. Recent studies have assessed the therapeutic potential of psilocybin for various conditions, including end-of-life anxiety, obsessive-compulsive disorder, and smoking and alcohol dependence, with promising preliminary results. Here, we aimed to investigate the feasibility, safety, and efficacy of psilocybin in patients with unipolar treatment-resistant depression. In this open-label feasibility trial, 12 patients (six men, six women) with moderate-to-severe, unipolar, treatment-resistant major depression received two oral doses of psilocybin (10 mg and 25 mg, 7 days apart) in a supportive setting. There was no control group. Psychological support was provided before, during, and after each session. The primary outcome measure for feasibility was patient-reported intensity of psilocybin's effects. Patients were monitored for adverse reactions during the dosing sessions and subsequent clinic and remote follow-up. Depressive symptoms were assessed with standard assessments from 1 week to 3 months after treatment, with the 16-item Quick Inventory of Depressive Symptoms (QIDS) serving as the primary efficacy outcome. This trial is registered with ISRCTN, number ISRCTN14426797. Psilocybin's acute psychedelic effects typically became detectable 30-60 min after dosing, peaked 2-3 h after dosing, and subsided to negligible levels at least 6 h after dosing. Mean self-rated intensity (on a 0-1 scale) was 0·51 (SD 0·36) for the low-dose session and 0·75 (SD 0·27) for the high-dose session. Psilocybin was well tolerated by all of the patients, and no serious or unexpected adverse events occurred. The adverse reactions we noted were transient anxiety during drug onset (all patients), transient confusion or thought disorder (nine patients), mild and transient nausea (four patients), and transient headache (four patients). Relative to baseline, depressive symptoms were markedly reduced 1 week (mean QIDS difference -11·8, 95% CI -9·15 to -14·35, p=0·002, Hedges' g=3·1) and 3 months (-9·2, 95% CI -5·69 to -12·71, p=0·003, Hedges' g=2) after high-dose treatment. Marked and sustained improvements in anxiety and anhedonia were also noted. This study provides preliminary support for the safety and efficacy of psilocybin for treatment-resistant depression and motivates further trials, with more rigorous designs, to better examine the therapeutic potential of this approach. Medical Research Council.

Twitter Demographics

The data shown below were collected from the profiles of 202 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 642 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 4 <1%
Brazil 3 <1%
Denmark 2 <1%
United Kingdom 1 <1%
Switzerland 1 <1%
Portugal 1 <1%
Russia 1 <1%
Finland 1 <1%
India 1 <1%
Other 0 0%
Unknown 627 98%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 166 26%
Student > Master 112 17%
Researcher 76 12%
Student > Ph. D. Student 69 11%
Unspecified 55 9%
Other 164 26%
Readers by discipline Count As %
Psychology 138 21%
Medicine and Dentistry 137 21%
Neuroscience 99 15%
Unspecified 78 12%
Biochemistry, Genetics and Molecular Biology 44 7%
Other 146 23%

Attention Score in Context

This research output has an Altmetric Attention Score of 2008. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 April 2019.
All research outputs
#687
of 12,837,341 outputs
Outputs from "The Lancet Psychiatry"
#3
of 1,351 outputs
Outputs of similar age
#31
of 262,613 outputs
Outputs of similar age from "The Lancet Psychiatry"
#1
of 71 outputs
Altmetric has tracked 12,837,341 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,351 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 71.5. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 262,613 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 71 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.